TW EN

scroll

Go Top

Overview

TCTC

Head and neck cancer and nasopharyngeal carcinoma are two of the most important cancers in Taiwan. The incidence of head and neck cancer continues to rise, ranking fourth and seventh most common malignancy in men and both sexes, respectively. Head and neck cancer is highly associated with tobacco, alcohol, betel nut and human papillomavirus infection. Nasopharyngeal carcinoma is highly associated with Epstein-Barr Virus infection, and the incidence rate is much higher in Taiwan compared to most western countries.

 

The prognosis of recurrent or metastatic head and neck cancer and nasopharyngeal carcinoma is extreme dismal. Furthermore, the choice of treatment options are very limited. Therefore, most of the oncologists and surgical oncologists treated patients by jointing the international clinical trials or PI initiated clinical trial. Our previous experience in clinical trials demonstrated we were well qualified and received recognition by international pharmaceutical company.

Strengths

TCTC

To facilitate performing good quality clinical trials in Taiwan, we plan to establish Head and neck cancer and nasopharyngeal carcinoma consortium for the following objectives:

  • To organize and establish the Taiwan Head and Neck Cancer and Nasopharyngeal Carcinoma Consortium group to collect clinical data and tissue specimen.
  • To help domestic company to perform clinical trial for generic drugs.
  • To perform PI initiated clinical trials
  • To help domestic company to develop novel drugs and translate to clinical trials.
  • To join more international clinical trials and complete the trial in time in this consortium.

Major Achievements

TCTC

The Head and Neck Cancer and Nasopharyngeal Carcinoma Alliance is an international collaborative alliance comprised of leading medical institutions, pharmaceutical manufacturers, and research organizations from around the world. This alliance is dedicated to research, diagnosis, and treatment of head and neck cancer and Nasopharyngeal Carcinoma, with the goal of improving patient survival rates and quality of life. One of the standout features of this alliance is its robust international collaboration network, which includes some key partners:

 
  • USA: The alliance collaborates with Pfizer, a pharmaceutical company based in the United States, to jointly develop innovative anti-cancer drugs, explore new treatment approaches, and expedite the progress of clinical trials.
  • Taiwan: This company is a renowned biopharmaceutical company in Taiwan, partnering with the alliance for the research and development of new drugs, focusing on innovative treatments for head and neck cancer and Nasopharyngeal Carcinoma.
  • Taiwan: A company dedicated to biomedical research and clinical trials, collaborating with the alliance to advance research in various new therapies.
  • UK: An internationally renowned pharmaceutical company based in the United Kingdom, collaborates with the alliance, providing technical support and expertise in drug development.
  • Taiwan: This Taiwanese company specializes in the development of biopharmaceuticals and works with the alliance to promote the application of biopharmaceuticals in the treatment of head and neck cancer and Nasopharyngeal Carcinoma.
  • USA: This company is a global pharmaceutical and diagnostic company headquartered in the United States. They partner with the alliance to conduct research and clinical trials related to head and neck cancer and esophageal cancer.
  • Switzerland: This company is a Swiss biopharmaceutical company collaborating with the alliance to explore new treatment approaches and innovate in cancer research.
  • National Institutes of Health, Taiwan: The National Institutes of Health in Taiwan is a national medical research institution. They collaborate with the alliance, providing research funding and resource support to advance research on head and neck cancer and esophageal cancer.
  • USA: This company is a global biopharmaceutical company headquartered in the United States. They collaborate with the alliance, dedicating their efforts to developing new biopharmaceuticals for more effective treatment options.
  • China: This company is a Chinese biopharmaceutical company partnering with the alliance to conduct research projects related to head and neck cancer and Nasopharyngeal Carcinoma.
  • USA: This is a global pharmaceutical company headquartered in the United States. They collaborate with the alliance, focusing on the development of new therapies such as immunotherapy and targeted treatments.
  • Germany: This is a well-known pharmaceutical company based in Germany. They collaborate with the alliance, jointly contributing to research and innovation in the field of cancer. The participation of these international partners allows the Head and Neck Cancer and Nasopharyngeal Carcinoma Alliance to leverage their respective expertise and resources, accelerate the development of new drugs and clinical trials, and provide better treatment options for patients with head and neck cancer and Nasopharyngeal Carcinoma, advancing cancer research and treatment.
 

In Taiwan, the number of new cases of head and neck cancer exceeds 10,000 every year, with the majority being in advanced stages, often requiring total laryngectomy surgery. The treatment team at Taipei Veterans General Hospital has developed a "preoperative chemoradiotherapy combination" approach, which reduces the size of tumors before surgery, preserving laryngeal function, and achieving a 70% three-year survival rate. Smoking, alcohol consumption, and betel nut chewing are the primary risk factors.

For example, Mr. Wu, a 60-year-old patient, underwent treatment that preserved his laryngeal function, and he has not experienced a recurrence. Early symptoms of head and neck cancer are often not apparent, leading to a high rate of late-stage diagnoses, emphasizing the importance of early detection and treatment. To prevent head and neck cancer, it is crucial to avoid carcinogenic factors, eliminate unhealthy habits, be vigilant about any neck abnormalities, and seek medical attention early. Taipei Veterans General Hospital has achieved excellent results in the treatment of head and neck cancer, enhancing the quality of life for patients.

Members

TCTC

Department of Oncology, Taipei Veterans General Hospital

Department of Oncology, Taipei Veterans General Hospital

Department of Oncology, Taipei Veterans General Hospital

Department of Oncology, Taipei Veterans General Hospital

Department of Oncology, Taipei Veterans General Hospital

Department of Oncology, Taipei Veterans General Hospital

Contact Information

c-IRB

Lai, Chia-Wei

Email:lrainv@gmail.com

TEL:(02)55704181 ext